Pharma/Biotech Update: NovoEight Provides Reduced Bleeding

Pharmaceutical company Novo Nordisk recently announced data from it’s phase 3 study on its upcoming recombinant coagulation factor VIII (8) product called NovoEight. It will be used as preventative treatment for those who suffer from hemophilia A, which is a factor VIII deficiency of the blood.

GuardianT2 is the extension of the pivotal guardianT clinical program, one of the largest and most comprehensive preregistration clinical trial programs in hemophilia, with more than 210 severe hemophilia A patients treated. GuardianT2 is an open-label, multinational, single-arm extension trial involving 188 hemophilia A patients from 18 countries who had been previously enrolled in the guardianT1 and guardianT3 trials. Patients received NovoEight in a preventative regimen and to treat breakthrough bleeds. 

“As a physician treating hemophilia A, having another FVIII product available is good news and can lead to improved treatment outcomes and quality of life for our patients. Reducing the number of bleeding episodes is a key consideration as they are very painful and frightening for patients and caregivers and can lead to severe long-term joint damage or arthropathy,” Dr. Margareth Ozelo, Hemocentre, IHTC, University of Campinas, Sao Paulo, Brazil said in a press release.

The results were presented at the World Federation of Hemophilia (WFH) World Congress that is ongoing this week in Melbourne, Australia from May 11-15.

Photo Credit – Novo Nordisk

webleed.org – your source for bleeding news!